SHH and idiopathic interstitial pneumonia: Taladegib (ENV‐101): Taladegib is a potent Shh signaling pathway inhibitor that binds to the human Smo receptor and competitively inhibits the binding of an Smo agonist.[557] Several phase II trials investigating the safety, tolerability, and impact of ENV‐101 on lung function and key measures of fibrosis in adult patients with IPF and progressive pulmonary fibrosis are ongoing (NCT06422884, NCT04968574).